SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+29.15%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$899M
AUM Growth
+$899M
(+15%)
Cap. Flow
+$33.5M
Cap. Flow
% of AUM
3.73%
Top 10 Holdings %
Top 10 Hldgs %
99.85%
Holding
13
New
1
Increased
7
Reduced
1
Closed
1
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$68.3M |
| 2 |
AbbVie
ABBV
|
$30.4M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$18M |
| 4 |
Alkermes
ALKS
|
$12.3M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
$5.31M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$82.8M |
| 2 |
Mersana Therapeutics
MRSN
|
$27.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $172M | 19.14% | 643,000 | – | – |
|
|
2
Alkermes
ALKS
$4.78B
| $152M | 16.89% | 7,825,000 +632,000 | +9% | +$12.3M |
|
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $145M | 16.12% | 14,040,000 +515,000 | +4% | +$5.31M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $102M | 11.39% | 928,100 +163,100 | +21% | +$18M |
|
5
Innoviva
INVA
$1.29B
| $89.7M | 9.98% | 6,414,000 +172,000 | +3% | +$2.4M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $83.5M | 9.28% | 743,500 +608,500 | +451% | +$68.3M |
|
|
7
Mersana Therapeutics
MRSN
$36.5M
| $60.1M | 6.69% | 2,570,000 -1,180,000 | -31% | -$27.6M |
|
|
ICPT
8
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $57.5M | 6.4% | 1,201,000 +46,000 | +4% | +$2.2M |
|
|
9
AbbVie
ABBV
$372B
| $30.5M | 3.39% | 310,150 +309,150 | +30,915% | +$30.4M |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.12M | 0.57% | +1,075,000 | New | +$5.12M |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $1.26M | 0.14% | 1,851,851 | – | – |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $114K | 0.01% | 1,000 | – | – |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| – | – | -467,500 | Closed | -$82.8M |
|